Literature DB >> 18550661

Phylogenetic and genetic analysis of feline immunodeficiency virus gag, pol, and env genes from domestic cats undergoing nucleoside reverse transcriptase inhibitor treatment or treatment-naïve cats in Rio de Janeiro, Brazil.

Angelica N Martins1, Sheila O Medeiros, Jose P Simonetti, Hermann G Schatzmayr, Amílcar Tanuri, Rodrigo M Brindeiro.   

Abstract

Feline immunodeficiency virus (FIV) is the Lentivirus responsible for an immunodeficiency-like disease in domestic cats (Felis catus). FIV is divided into five phylogenetic subtypes (A, B, C, D, and E), based on genetic diversity. Knowledge of the geographical distribution of subtypes is relevant for understanding different disease progressions and for vaccine development. In this study, viral sequences of 26 infected cats from Rio de Janeiro, 8 undergoing treatment with zidovudine (AZT) for at least 5 years, were successfully amplified from blood specimens. gag capsid (CA), pol reverse transcriptase (RT), and env gp120 (V3-V4) regions were analyzed to determine subtypes and to evaluate potential mutations related to antiretroviral drug resistance among treated cats. Subtyping based on phylogenetic analysis was performed by the neighbor-joining and maximum likelihood methods. All of the sequences clustered with subtype B in the three regions, exhibiting low genetic variability. Additionally, we found evidence that the same virus is circulating in animals in close contact. The analysis of FIV RT sequences identified two new putative mutations related to drug resistance located in the RT "finger" domain, which has 60% identity to human immunodeficiency virus (HIV) sequence. Amino acid change K-->R at codons 64 and 69 was found in 25% and 37.5% of the treated animals, respectively. These signatures were comparable to K65R and K70R thymidine-associated mutations found in the HIV-1 HXB2 counterpart. This finding strongly suggests a position correlation between the mutations found in FIV and the K65R and K70R substitutions from drug-resistant HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550661      PMCID: PMC2519550          DOI: 10.1128/JVI.00310-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.

Authors:  Sudhir Kumar; Koichiro Tamura; Masatoshi Nei
Journal:  Brief Bioinform       Date:  2004-06       Impact factor: 11.622

3.  Feline immunodepressive retrovirus infections in France.

Authors:  A Moraillon
Journal:  Vet Rec       Date:  1990-01-20       Impact factor: 2.695

4.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

5.  Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change.

Authors:  M A Rigby; E C Holmes; M Pistello; A Mackay; A J Brown; J C Neil
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

6.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  D Zhang; A M Caliendo; J J Eron; K M DeVore; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns.

Authors:  D L Sodora; E G Shpaer; B E Kitchell; S W Dow; E A Hoover; J I Mullins
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in Ontario, Canada.

Authors:  F Reggeti; D Bienzle
Journal:  J Gen Virol       Date:  2004-07       Impact factor: 3.891

10.  Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats.

Authors:  W K Greene; J Meers; G del Fierro; P R Carnegie; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more
  10 in total

1.  Identification of a novel subtype of feline immunodeficiency virus in a population of naturally infected felines in the Brazilian Federal District.

Authors:  T G Marçola; C P C Gomes; P A Silva; G R Fernandes; G R Paludo; R W Pereira
Journal:  Virus Genes       Date:  2013-01-18       Impact factor: 2.332

2.  Genetic data generated from virus-host complexes obtained by membrane co-immobilization are equivalent to data obtained from tangential filtrate virus concentrates and virus cultures.

Authors:  J M Manrique; L R Jones
Journal:  Virus Genes       Date:  2013-10-29       Impact factor: 2.332

Review 3.  FIV Gag: virus assembly and host-cell interactions.

Authors:  Benjamin G Luttge; Eric O Freed
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

4.  Natural transmission of feline immunodeficiency virus from infected queen to kitten.

Authors:  Sheila de Oliveira Medeiros; Angelica Nascimento Martins; Carlos Gabriel Almeida Dias; Amilcar Tanuri; Rodrigo de Moraes Brindeiro
Journal:  Virol J       Date:  2012-05-25       Impact factor: 4.099

5.  Phylogenetic characterisation of naturally occurring feline immunodeficiency virus in the United Kingdom.

Authors:  A Samman; E L McMonagle; N Logan; B J Willett; R Biek; M J Hosie
Journal:  Vet Microbiol       Date:  2011-02-01       Impact factor: 3.293

Review 6.  Feline immunodeficiency virus in South America.

Authors:  Bruno M Teixeira; Mitika K Hagiwara; Juliano C M Cruz; Margaret J Hosie
Journal:  Viruses       Date:  2012-03-14       Impact factor: 5.818

7.  Feline Immunodeficiency Virus Evolutionarily Acquires Two Proteins, Vif and Protease, Capable of Antagonizing Feline APOBEC3.

Authors:  Rokusuke Yoshikawa; Junko S Takeuchi; Eri Yamada; Yusuke Nakano; Naoko Misawa; Yuichi Kimura; Fengrong Ren; Takayuki Miyazawa; Yoshio Koyanagi; Kei Sato
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

8.  Clinical and Molecular Features of Feline Foamy Virus and Feline Leukemia Virus Co-Infection in Naturally-Infected Cats.

Authors:  Liliane T F Cavalcante; Cláudia P Muniz; Hongwei Jia; Anderson M Augusto; Fernando Troccoli; Sheila de O Medeiros; Carlos G A Dias; William M Switzer; Marcelo A Soares; André F Santos
Journal:  Viruses       Date:  2018-12-11       Impact factor: 5.048

9.  Feline immunodeficiency virus in Northern Ceará, Brazil.

Authors:  Bruno Marques Teixeira; Sueli Akemi Taniwaki; Poliana Marisa Miranda Menezes; Ana Kétylla Ponte Prado Rodrigues; Andressa Nunes Mouta; Thiago Luiz Mendes Arcebispo; Gissandra Farias Braz; Juliano Cezar Minardi da Cruz; Paulo Eduardo Brandão; Marcos Bryan Heinemann; Marcos Xavier Silva; Margaret J Hosie
Journal:  JFMS Open Rep       Date:  2019-07-08

10.  Decreased Sensitivity of the Serological Detection of Feline Immunodeficiency Virus Infection Potentially Due to Imported Genetic Variants.

Authors:  Julia Frankenfeld; Theres Meili; Marina L Meli; Barbara Riond; A Katrin Helfer-Hungerbuehler; Eva Bönzli; Benita Pineroli; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2019-07-31       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.